The von Hippel-Lindau Tumor Suppressor Gene Mutations Modulate Lipocalin-2 Expression in Ferroptotic-Inflammatory Pathways
Oxidative Medicine and Cellular Longevity · 2023
DOI: 10.1155/2023/7736638 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oxidative Medicine and Cellular Longevity, 2023. Verfasst von Chan-Yen Kuo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Lipocalin-2, Von Hippel-Lindau Tumor Suppressor Protein. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Buddhist Tzu Chi Medical Foundation, Taipei Tzu Chi Hospital, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
A previous study of an animal model with tumor suppressor gene von Hippel-Lindau (VHL) conditional knockdown suggested that tissue inflammation and fibrosis play important roles in the development of clear-cell renal cell carcinoma (ccRCC), which is consistent with the epidemiological evidence linking inflammatory kidney disease and renal cancer. Ferroptosis and inflammation have been linked in a recent study, but the exact mechanism remains unclear. This study is aimed at investigating the mechanism of lipocalin-2- (LCN-2-) mediated ferroptosis and inflammation in vhl-mutated HK-2 cells and mouse primary proximal tubule cells (mRTCs) and the polarization of macrophage RAW 264.7 cells. Based on the levels of lipid reactive oxygen species (ROS) and the expression of glutathione peroxidase 4 (GPX4) in HK-2 cells, we observed that a VHL mutation increased ROS production and depressed GPX4 expression, whereas LCN-2 knockdown reversed these effects. Accordingly, VHL appears to affect ferroptosis in an LCN-2-dependent manner. We also revealed that LCN-2 sensitizes HK-2 cells to inflammation and macrophage RAW 264.7 cells to M1-like polarization. This study provides novel insights into the potential therapeutic target and strategy for attenuating the progression of ccRCC by revealing the role of VHL in regulating chronic inflammation within the LCN-2–ferroptosis pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan.
- Department of Nursing, Cardinal Tien College of Healthcare and Management, New Taipei City 231, Taiwan.
- Department of Medical Technology, Jenteh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan.
- Department of Chinese Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
- Division of Physical Medicine and Rehabilitation, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan.
- School of Medicine, Tzu Chi University, Hualien 970, Taiwan.
ORCID-Profile: Chan-Yen Kuo, Valeria Chiu
Förderung
- Buddhist Tzu Chi Medical Foundation
- Taipei Tzu Chi Hospital
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Kuo, C. Y., Hsieh, P. C., Chiu, V., Lan, C. C., & Lu, K. C. (2023). The von Hippel-Lindau Tumor Suppressor Gene Mutations Modulate Lipocalin-2 Expression in Ferroptotic-Inflammatory Pathways. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2023/7736638
Vancouver
Kuo CY, Hsieh PC, Chiu V, Lan CC, Lu KC. The von Hippel-Lindau Tumor Suppressor Gene Mutations Modulate Lipocalin-2 Expression in Ferroptotic-Inflammatory Pathways. Oxidative Medicine and Cellular Longevity. 2023. doi:10.1155/2023/7736638
BibTeX
@article{Kuo2023,
author = {Kuo, Chan-Yen and Hsieh, Po-Chun and Chiu, Valeria and Lan, Chou-Chin and Lu, Kuo-Cheng},
title = {The von Hippel-Lindau Tumor Suppressor Gene Mutations Modulate Lipocalin-2 Expression in Ferroptotic-Inflammatory Pathways},
journal = {Oxidative Medicine and Cellular Longevity},
year = {2023},
doi = {10.1155/2023/7736638}
}
EUVIMED